Intralesional corticosteroid treatment of multiple eruptive keratoacanthomas: case report and review of a controversial therapy.
BACKGROUND
Use of intralesional corticosteroids in the management of keratoacanthomas has been reported in older literature. Yet this therapy is no longer a commonly considered treatment option.


OBJECTIVE
To report management of a therapeutically challenging patient with multiple eruptive keratoacanthomas with intralesional corticosteriod treatment to revive awareness of this treatment option.


METHODS
A 55-year-old female with frequent episodes of multiple eruptive keratoacanthomas was treated with intralesional corticosteroids and methotrexate.


RESULTS
Intralesional corticosteroids successfully treated eruptive keratoacanthomas with complete regression and minimal scarring within 2-4 weeks.


CONCLUSIONS
Despite its limitations, intralesional corticosteroids may have a role in the treatment of select keratoacanthomas.
Sanders
Scott
S
Dermatology Service and Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA.
Busam
Klaus J
KJ
Halpern
Allan C
AC
Nehal
Kishwer S
KS
D001132:Arm; D003879:Dermatologic Agents / Q000627:therapeutic use; D005260:Female; D005938:Glucocorticoids / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D015552:Injections, Intralesional; D007636:Keratoacanthoma / Q000188:drug therapy*; D007866:Leg; D008727:Methotrexate / Q000627:therapeutic use; D008875:Middle Aged; D014221:Triamcinolone / Q000008:administration & dosage / Q000627:therapeutic use*
D003879:Dermatologic Agents; D005938:Glucocorticoids; D014221:Triamcinolone; D008727:Methotrexate